DEA genes that were down-regulated in basal-like PDOs with prognostic impact in the PanGen patient cohort included SLCO2A1, CEACAM7 and NR5A2. SLCO2A1 encodes a bidirectional prostaglandin transporter PGT and its low expression is associated with worse prognosis in gastric and breast cancers [45, 46]. Here, NR5A2 is linked to breast carcinoma.